1[1]Harris CC.The 1995 Walter Hubert lecture-molecular epidemiology of human cancer:insights from the mutation analysis of the P53 tumor suppressor gene[J].British journal of cancer,1996,73:261-269.
2[3]Agaoglu FY,Dizdar Y,Dogan O.P53 overexpression in nasopharyngeal carcinoma[J].In Vivo,2004,18(5):555-560.
3[4]Greenblatt MS.Mutations in the P53 tumor suppressor gene:c1ues to Cancer etiology and molecular pathogenesis[J].Can Res,l994,54:4855-4878.
4[5]Burgos JS.Absence of p53 alterations in nasopharyngeal carcinoma Spanish patients with Epstein-Barr virus infection[J].Virus Genes,200327(3):263-268.
6[9]Ardila-Osorio H,Pioche-2Durieu C,Puvion-Dutilleul F,et al.TRAF interactions with raft-like buoyant complexes,better than TRAF rates of degradation,differentiate signaling by CD40 and EBV latent membrane protein 1[J].Int J Cancer,2005,113(2):267-275.
7[10]Sheu LF,Chen A,Lee HS,et al.Cooperative interactions among p53,bcl-2 and Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells[J].Pathol int,2004,54(7):475-485.
8Koshland DE Jr.Molecular of the year[J].Science,1993,262:1953
9Kamijo T,Weber JD,Zambetti G,et al.Functional and physical interactions of the ARF tumor suppressor with P53 and ndm2[J].Proc Natl Acad sci USA,1998,95:8 292
10Powell B,Soong R,Iacopetta B,et al.Prognostic significance of mutations to different structure and funtional regions of the P53 gene in breast cancer[J].Clin Can Res,2000,6:443
